Brii Biosciences Limited

Research Brii Biosciences Limited (7SS) on Bullrun: market cap EUR 69.95M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 69.95M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025CNY 18.61M-CNY 222.62M-CNY 465.80Mn/a-0.31CNY 606.84MCNY 8.93MCNY 2.38B
FY2024CNY 0-CNY 508.16M-CNY 376.12Mn/a-0.7CNY 1.00BCNY 28.02MCNY 2.66B
FY2023CNY 617.00K-CNY 174.83M-CNY 643.62Mn/a-0.24CNY 489.65MCNY 3.16MCNY 3.12B
FY2022CNY 51.63M-CNY 484.31M-CNY 635.57Mn/a-0.67CNY 1.19BCNY 12.66MCNY 3.19B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-14EUR 69.95Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About Brii Biosciences Limited

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Brii Biosciences Limited's market cap?

Brii Biosciences Limited's market capitalization is EUR 69.95M.

What does Brii Biosciences Limited do?

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States.